Antifungal pharmaceutical compositions and uses thereof
A technology of antifungal drugs and compositions, applied in the directions of antifungal agents, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve the problems of research reports, there is no antifungal effect of Candida albicans, etc., and achieve reversal of drug resistance the effect of enhancing antibacterial activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0035] Example 1: Determination of static effect of Oridonin A combined with triazoles against Candida albicans
[0036] 1. Materials
[0037] 1.1 Experimental strains
[0038] Quality control standard strain: Candida albicans (C.albicans, CA) standard strain CA (obtained from the American Type Culture Collection with the accession number ATCC 10231).
[0039] Experimental strain: Candida albicans isolated clinically. The Candida albicans used in the experiment were all samples submitted by clinical patients in the Laboratory Department of Shandong Cancer Hospital. The obtained Candida albicans strains were numbered CA173, CA195, CA2489 and CA3208 respectively, and according to the results of the drug susceptibility test, CA173 and CA195 were Candida albicans resistant to triazoles, while CA2489 and CA3208 were triazole-resistant Candida albicans. Azole-sensitive Candida albicans.
[0040] 1.2 Drugs and reagents
[0041] Fluconazole (FLC), itraconazole (ITR) and voriconazo...
Embodiment 2
[0083] Example 2: Determination of the dynamic effect of Oridonin A and triazole drugs combined against Candida albicans
[0084] 1. Materials
[0085] 1.1 Strains
[0086] The strain used in the experiment was clinically isolated triazole-resistant Candida albicans CA173, which was identified and confirmed by CHROMagar yeast identification medium, and subcultured on solid medium.
[0087] 1.2 Drugs and reagents
[0088] The bulk drug of ORI, FLC, ITR and VOR; Dimethyl sulfoxide DMSO; PBS damping fluid; 0.1mol / L NaOH solution; RPMI 1640; 1 is the same.
[0089] 1.3 Instruments
[0090] MMM constant temperature incubator, high temperature and high pressure sterilizer, biological safety cabinet (all the same as the above-mentioned embodiment 1); constant temperature oscillator (Germany GFL company).
[0091] 2. Content and method
[0092] In this experiment, the drug single-use and drug-combination action systems were established, and the culture was shaken at 35°C for 48h...
Embodiment 3
[0105] Example 3: Study on the mechanism of action of Rubescensine A combined with triazoles against Candida albicans
[0106] 1. Materials and Instruments
[0107] Experimental strain: clinically isolated Candida albicans CA173, thawed from -20°C refrigerator, subcultured on YPD solid medium for at least 3 times and recovered before use.
[0108] Medium: The preparation method of YPD liquid medium is as follows: Weigh 4g of yeast extract, 8g of peptone and 8g of glucose respectively, add an appropriate amount of distilled water and stir to dissolve it as much as possible, then add distilled water to 400ml, and stir well. Finally, autoclave at 121°C for 20 minutes, cool and store in a refrigerator at 4°C. YPD solid medium is a medium for daily inoculation culture, and its preparation method is the same as above.
[0109] Drug solution: Oridonin A mother solution was diluted to 32 μg / ml with RPMI 1640 medium (same as in Example 1 above), and set aside.
[0110] Reagents and ...
PUM
| Property | Measurement | Unit |
|---|---|---|
| concentration | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More